3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
35
Lung Neoplasms
9
Neoplasms
6
Neoplasm Metastasis
5
Carcinoma
5
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thoracic Neoplasms
1
Stage IB-IIIA Non-small Cell Lung Carcinoma
1
Skin Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Noonan Syndrome
1
Non Small Cell Lung Cancer Metastatic
1
Neoplasms, Squamous Cell
1
Neoplasms by Site
1
NSCLC
1
Multiple Myeloma
1
Lymphoma
1
Lung Diseases
1
Locally Advanced or Metastatic EGFR T790M+ NSCLC
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Hematologic Neoplasms
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Interventions
tremelimumab
1
trametinib
1
pazopanib
1
eribulin
1
durvalumab
1
HhAntag691
1
Gemcitabine
1
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Hemangioendothelioma, Epithelioid
×
osimertinib
×
Clear all
No trials found.